Marinus Pharmaceuticals, Inc.
$5.6M 988 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. reported $5,615,816.53 across General Payments, Research, and Ownership to 5,247 physicians and teaching hospitals across 7,322 transactions.
- $5.6M Top quartile payer
- All-tracks total
- 7,322 Top quartile volume
- Transactions
- 5,247 Top quartile reach
- Recipients
- −$165.4K
- General Payments vs PY2023
Karyopharm Therapeutics Inc. reported $5,615,816.53 across all CMS Open Payments tracks (General + Research + Ownership) to 5,247 physicians and teaching hospitals in Program Year 2024 - ranking #259 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,006,759.59, averaging $1.1K per recipient.
How Karyopharm Therapeutics Inc.'s $5.6M all-tracks total breaks down
Karyopharm Therapeutics Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
66/100
Total payments
D
62/100
Transaction volume
D
63/100
Physician reach
D
50/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer karyopharm-therapeutics-inc Karyopharm Therapeutics Inc.
$5.6M · #259/1,925 · 0.0% industry · PY2024
- TOT $5.6M
- RANK #259
- SHARE 0.0%
- TXN 7,322
- RCP 5,247
- CAT 7
- GEN $1.0M
- ΔGEN −$165.4K
- TOP1 5.4%
- PY 2024
Volume peers
Nearest volume peer: Marinus Pharmaceuticals, Inc. ($5.6M)
Karyopharm Therapeutics Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Karyopharm Therapeutics Inc.'s CMS-reported General Payments decreased by $165.4K (−14.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: KARYOPHARM THERAPEUTICS INC.PY2023: KARYOPHARM THERAPEUTICS INC.PY2024: Karyopharm Therapeutics Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,172,114.61
- PY2024
- $1,006,759.59
What the Data Shows for Karyopharm Therapeutics Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Karyopharm Therapeutics Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
141 transactions worth $429.8K make "Honoraria" the top general-payment category in the 7-category breakdown below, 42.7% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Honoraria" leads Karyopharm Therapeutics Inc.'s 7-category general-payment breakdown at $429.8K, 42.7% of the reported total.
Karyopharm Therapeutics Inc. reports 7 general-payment categories - the top three are Honoraria (42.7%), Consulting Fee (23.1%), and Travel and Lodging (13.4%). The remaining 4 categories make up 20.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Karyopharm Therapeutics Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $429.8K | 141 | 42.7% |
| Consulting Fee | $232.3K | 109 | 23.1% |
| Travel and Lodging | $134.6K | 269 | 13.4% |
| Food and Beverage | $129.2K | 4,711 | 12.8% |
| Space Rental or Facility Fees | $65.7K | 7 | 6.5% |
| Grant | $15.0K | 1 | 1.5% |
| Education | $92.71 | 9 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $219,316.52 (21.8%) of $1,006,759.59 in this company's General Payments records across 2,891 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Karyopharm Therapeutics Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Hakan Kaya
$54,164.40 across 33 reported transactions
- 2
Mount Sinai Hospital
$49,600.00 across 2 reported transactions
- 3
Matthew M Burke
$43,911.08 across 82 reported transactions
- 4
Taral Patel
$38,329.79 across 31 reported transactions
- 5
Kelly Mccaul
$33,311.25 across 17 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Karyopharm Therapeutics Inc. ranks #259 of 1,925 by total payments (top 13% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,584 of 1,838 by HHI (bottom 14% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Ascensia Diabetes Care Us Inc. : $258.2K total payments, HHI 181
- Conetic Solutions, Inc. : $36.7K total payments, HHI 180
- Pacira Pharmaceuticals Incorporated : $4.8M total payments, HHI 178
- Novo Nordisk AS : $2.4M total payments, HHI 178
- Omeza LLC : $1.5K total payments, HHI 178
- Caldera Medical, Inc : $117.1K total payments, HHI 177
- Karyopharm Therapeutics Inc. (this company) : $1.0M total payments, HHI 177
- Sagent Pharmaceuticals : $1.0K total payments, HHI 177
- Rigel Pharmaceuticals, Inc. : $1.0M total payments, HHI 175
- Servier Pharmaceuticals LLC : $1.5M total payments, HHI 174
- Mirati Therapeutics, Inc. : $322.0K total payments, HHI 171
- Sekisui Diagnostics, LLC : $21.5K total payments, HHI 171
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Karyopharm Therapeutics Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Karyopharm Therapeutics Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Karyopharm Therapeutics Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Providence Medical Technology, Inc.
$5.6M 2,215 recipients
Compare payment profiles
DeRoyal Industries, Inc.
$5.6M 82 recipients
Compare payment profiles
Ascendis Pharma Inc
$5.7M 2,549 recipients
Compare payment profiles
Nalu Medical, Inc.
$5.7M 9,707 recipients
Compare payment profiles
Highridge Medical LLC
$5.8M 2,278 recipients
Compare payment profiles
Put this to use
Karyopharm Therapeutics Inc. ranks #259 of 1,925 by all-tracks total payments, led by "Honoraria".
- See where Karyopharm Therapeutics Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Karyopharm Therapeutics Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.